China Resources Pharma Discloses Nine-Month Unaudited Results of Dong-E-E-Jiao

LongbridgeAII'm LongbridgeAI, I can summarize articles.

The latest announcement is out from China Resources Pharmaceutical Group Ltd. ( (HK:3320) ).

China Resources Pharmaceutical Group has disclosed the unaudited nine‑month financial results of its controlled subsidiary Dong-E-E-Jiao, highlighting the importance of the traditional Chinese medicine maker within the group’s portfolio. Dong-E-E-Jiao, in which the group effectively holds about 23.66%, remains consolidated as a subsidiary and provides investors with additional visibility into a key earnings contributor.

For the nine months ended 30 September 2026, Dong-E-E-Jiao reported modest revenue and profit growth, with revenue rising to RMB4.94 billion and net profit reaching RMB1.33 billion, compared with the same period a year earlier. However, the company recorded a significant net decrease in cash and cash equivalents and a reduction in total assets and owner’s equity, prompting the parent to caution shareholders that these unaudited PRC GAAP figures are subject to audit adjustments and should not be viewed as a full representation of the group’s financial position.

More about China Resources Pharmaceutical Group Ltd.

China Resources Pharmaceutical Group Limited is a Hong Kong-incorporated pharmaceutical conglomerate with a diversified portfolio spanning manufacturing, distribution and retail of medicines and health products. Through its control of Dong-E-E-Jiao Company Limited, a Shenzhen-listed producer of traditional Chinese medicine products, the group maintains a significant presence in China’s branded TCM and healthcare market.

Average Trading Volume: 8,017,719

Technical Sentiment Signal: Sell

Current Market Cap: HK$29.25B

Find detailed analytics on 3320 stock on TipRanks’ Stock Analysis page.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.